Cargando…
Glucose-lowering therapy in type 2 diabetes: New hope after the EMPA-REG outcome trial
Prevention of cardiovascular morbidity and mortality remains the key factor in the treatment of type 2 diabetes (T2DM). In the early phase of T2DM, multifactorial intervention is mandatory and glucose levels should be near normal, in particular in younger patients presenting with the highest cardiov...
Autores principales: | Schernthaner, G., Schernthaner, G.-H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839058/ https://www.ncbi.nlm.nih.gov/pubmed/27071968 http://dx.doi.org/10.1007/s00059-016-4427-3 |
Ejemplares similares
-
Clinical implications of cardiovascular outcome trials in type 2 diabetes
por: Mellbin, L. G., et al.
Publicado: (2019) -
Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial
por: Alzaid, Aus
Publicado: (2017) -
Bladder cancer in the EMPA-REG OUTCOME trial
por: Kohler, Sven, et al.
Publicado: (2017) -
Vascular legacy: HOPE ADVANCEs to EMPA-REG and LEADER: A Surprising similarity
por: Kalra, Sanjay, et al.
Publicado: (2017) -
An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis: Immunotherapy with rituximab, ocrelizumab, and ofatumumab
por: Ovchinnikov, Arkady, et al.
Publicado: (2022)